Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.91 |
| ▸ | MMP2 | P08253 | 13/20 | 0.91 |
| ▸ | MMP3 | P08254 | 10/20 | 0.91 |
| ▸ | MMP13 | P45452 | 10/20 | 0.91 |
| ▸ | MMP1 | P03956 | 9/20 | 0.91 |
| ▸ | MMP7 | P09237 | 9/20 | 0.91 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.72 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.72 |
| ▸ | MMP14 | P50281 | 1/20 | 0.68 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964630 | 1.00 | MMP9 (0.91) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL6446613 | 1.00 | MMP9 (0.91) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7870625 | 0.95 | MMP2 (1.00) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7870619 | 0.95 | MMP2 (1.00) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL6800772 | 0.91 | MMP2 (0.77) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL8446281 | 0.91 | MMP9 (1.00) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL6302637 | 0.89 | MMP9 (0.73) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL21538657 | 0.89 | MMP9 (0.73) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL6296214 | 0.89 | MMP9 (0.73) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL27485402 | 0.88 | MMP2 (0.80) | MMP9MMP2MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-111989331-B | Synthesis method of 2- [ (2S) -1-azabicyclo [2.2.2] oct-2-yl ] -6- (3-methyl-1H-pyrazol-4-yl) thieno [3,2-d ] pyrimidine-4 (3H) -ketone | 武田药品工业株式会社 | 2024-04-12 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11524957-B2 | Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-13 | — | — | US | disclosed |
| US-11524957-B2 | Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-13 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20210101897-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-08 | — | — | US | disclosed |
| EP-3641891-A1 | SYNTHESIS OF DISORAZOLES AND ANALOGS THEREOF AS POTENT ANTICANCER AGENTS | William Marsh Rice University (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019194319-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6- (3-METHYL-1 H-PYRAZOL-4-YL)THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018237178-A1 | SYNTHESIS OF DISORAZOLES AND ANALOGS THEREOF AS POTENT ANTICANCER AGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20080161580-A1 | PROTECTED 3,5-DIHYDROXY-2,2-DIMETHYL-VALEROAMIDES FOR THE SYNTHESIS OF EPOTHILONES AND DERIVATIVES AND PROCESS FOR THE PRODUCTION AND THE USE | WESTERMANN JURGEN | 2008-07-03 | — | — | US | disclosed |
| US-7368568-B2 | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for production and the use | BAYER SCHERING PHARMA AG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050272731-A1 | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for production and the use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-6933385-B2 | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use | SCHERING AG (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20030158412-A1 | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524957-B2 | Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one | CDC7, CDK7, CDCA2 | MMP9 4314/4885MMP2 4637/4885MMP3 4747/4885 |
| US-20080161580-A1 | PROTECTED 3,5-DIHYDROXY-2,2-DIMETHYL-VALEROAMIDES FOR THE SYNTHESIS OF EPOTHILONES AND DERIVATIVES AND PROCESS FOR THE PRODUCTION AND THE USE | DHPS, VARS1, CYP51A1 | MMP9 2153/4885MMP2 1759/4885MMP3 1378/4885 |
| US-20030158412-A1 | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use | DHPS, VARS1, CYP51A1 | MMP9 2153/4885MMP2 1759/4885MMP3 1378/4885 |
| US-20210101897-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE | CDC7, CDK7, CDCA2 | MMP9 4310/4885MMP2 4634/4885MMP3 4742/4885 |
| US-20050272731-A1 | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for production and the use | DHPS, VARS1, HSD17B12 | MMP9 2547/4885MMP2 1649/4885MMP3 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.